Skip to main content

Nasdaq IPOs

Ares Management's SPAC Ares Acquisition files for a $600 million IPO

5 years 8 months ago
Ares Acquisition, a blank check company formed by Ares Management targeting a sustainable business, filed on Friday with the SEC to raise up to $600 million in an initial public offering. The New York, NY-based company plans to raise $600 million by offering 60 million units at
Renaissance Capital

US IPO Week Ahead: Foreign issuers dominate a 4 IPO week

5 years 8 months ago
Four IPOs are scheduled to raise $1.8 billion in the shortened holiday week, featuring a diverse group of foreign issuers.   China’s leading e-cigarette brand RLX Technology (RLX) plans to raise $1.0 billion at a $14.0 billion market cap. RLX Technology sells e-cigaret
Renaissance Capital

PurposeBuilt Brands files for a $100 million IPO

5 years 8 months ago
PurposeBuilt Brands, which provides specialty cleaning and disinfecting products, filed on Friday with the SEC to raise up to $100 million in an initial public offering.  PurposeBuilt Brands offers specialty cleaning and disinfecting products from a portfolio of household c
Renaissance Capital

COVID-19 test maker LumiraDx files for a $100 million US IPO

5 years 8 months ago
LumiraDx, a UK-based provider of point-of-care diagnostics including COVID-19 tests, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company aims to bring lab-comparable performance to the point-of-care in minutes on a single instrumen
Renaissance Capital

Phase 3 biotech Angion Biomedica files for a $75 million IPO

5 years 8 months ago
Angion Biomedica, a Phase 3 biotech developing small molecule therapies for acute organ injuries, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The company had previously filed to raise $30 million in May 2014 but withdrew the following Oc
Renaissance Capital

Cancer biotech Immunocore files for a $100 million US IPO

5 years 8 months ago
Immunocore Holdings, Phase 3 biotech developing T Cell therapies for cancer and other diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The Abingdon, United Kingdom-based company was founded in 2007 and booked $39 million in milest
Renaissance Capital

Cell therapy biotech Vor Biopharma files for a $150 million IPO

5 years 8 months ago
Vor Biopharma, a Phase 1/2 biotech developing cell therapies for hematological diseases, filed on Friday with the SEC to raise up to $150 million in an initial public offering. The company's pipeline contains its lead engineered hematopoietic stem cell (eHSC) candidate, VOR
Renaissance Capital

Dutch rare disease biotech Pharvaris files for a $100 million US IPO

5 years 8 months ago
Pharvaris, a Dutch Phase 1 biotech developing small molecule therapies for rare diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company is focused on the development of innovative therapies for rare diseases with significant
Renaissance Capital
Checked
17 minutes 20 seconds ago
This feed is responsible for generating the rss feed related to the topic IPOs
Subscribe to Nasdaq IPOs feed